Evommune opened lower at $8.58, compared with its previous close of $8.62. In the last trading session, the stock traded between $7.74 and $8.58. It showed a downward intraday trend.
An investment of $100 made 2 years ago in Evommune is now worth
$ 39.63
Resulting in a loss of
$ 60.37 (60.37%)
Note: Past profits do not guarantee future returns.
Rating from 11 Analysts
Today's Change
$-0.60 (-7.00%)
Day High
$8.58
Day Low
$7.74
Day Open
$8.58
Prev Close
$8.62
Volume
10,76,554
1W Return
32.67%
1M Return
32.32%
3M Return
-43.46%
6M Return
-65.46%
1Y Return
-58.82%
Market Cap ($ Mn)
291
PE Ratio
-
PB Ratio
1.73
PEG Ratio
-
ROE
-
ROCE
-80.33%
EPS (TTM)
-
1 Week
32.67%
1 Month
32.32%
3 Months
-43.46%
6 Months
-65.46%
9 Months
-71.83%
Evommune Q3 Results: Loss per share widens to $0.85, misses estimate
Loss per share of $0.85 missed the analyst estimate of $0.84 by 1.19%. Quarterly loss widened compared to the same period last year according to source text. Source figures show current loss of $0.85 against prior year loss of $8.07.
TodayEvommune schedules investor presentations at three healthcare conferences
Evommune will present at Stifel Healthcare Conference on November 11, 2026. Management scheduled for Jefferies Global Healthcare Conference on November 18, 2026. Evercore Healthcare Conference presentation set for December 2, 2026. Webcasts available on company website with 30-day archived replays.
3 days agoEvommune inks $30M upfront deal with Hinova for EVO570 license
Evommune secures exclusive license for EVO570 outside Greater China. Upfront payment totals $30 million ($20M cash, $10M warrants). Potential milestones reach approximately $1.1 billion plus royalties. Phase 1 trial expected to begin imminently; Phase 2 planned for 2027. EVO570 is an oral VAV1-directed molecular glue degrader for autoimmune diseases.
8 days agoEvommune secures $30 million through private placement of shares
Raised approximately $30 million in gross proceeds. Sold 4,966,889 shares at $6.04 per share. Proceeds to fund EVO570 clinical development. Morgan Stanley and Leerink Partners served as placement agents.
8 days agoEvommune to present EVO301 Phase 2a data at EADV Congress 2026
Evommune will present Phase 2a data for EVO301 at EADV Congress in Vienna. Late-breaking oral session scheduled for October 1, 2026. EVO301 targets IL-18, an upstream driver of inflammation in atopic dermatitis. Company estimates 29 million patients need advanced therapy for moderate-to-severe AD. Phase 2b dose-ranging study anticipated to begin in mid-2027.
1mo agoEvommune halts EVO756 in atopic dermatitis after missing Phase 2b endpoint
EVO756 missed primary and secondary endpoints in Phase 2b atopic dermatitis trial. Trial enrolled 121 adults; drug showed no efficacy across all doses. Evommune will not advance EVO756 in atopic dermatitis indication. Company continues Phase 2b development of EVO756 for migraine prophylaxis. EVO301 becomes lead atopic dermatitis program after positive Phase 2a data.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 2 years ago in Evommune is now worth
$ 39.63
Resulting in a loss of
$ 60.37 (60.37%)
Note: Past profits do not guarantee future returns.
